Faron Pharmaceuticals Oy (FARN) Competitors GBX 207 +4.50 (+2.22%) As of 07/25/2025 09:54 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock FARN vs. ERGO, SLN, PRTC, OXB, HZD, VRP, ARIX, BVXP, CIR, and 4BBShould you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), Circassia Group (CIR), and 4basebio (4BB). These companies are all part of the "biotechnology" industry. Faron Pharmaceuticals Oy vs. Its Competitors Ergomed Silence Therapeutics PureTech Health Oxford Biomedica Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) Arix Bioscience Bioventix Circassia Group 4basebio Ergomed (LON:ERGO) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends. Does the media refer more to ERGO or FARN? In the previous week, Ergomed's average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score. Company Overall Sentiment Ergomed Neutral Faron Pharmaceuticals Oy Neutral Which has higher earnings & valuation, ERGO or FARN? Ergomed has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErgomed£152.09M0.00£15M£0.29N/AFaron Pharmaceuticals OyN/AN/A-£60.23M-£37.39-5.54 Is ERGO or FARN more profitable? Ergomed has a net margin of 9.87% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Ergomed's return on equity of 18.08% beat Faron Pharmaceuticals Oy's return on equity.Company Net Margins Return on Equity Return on Assets Ergomed9.87% 18.08% 10.16% Faron Pharmaceuticals Oy N/A 0.46%-70.00% Which has more risk & volatility, ERGO or FARN? Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Faron Pharmaceuticals Oy has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ERGO or FARN? 71.1% of Ergomed shares are held by institutional investors. Comparatively, 10.7% of Faron Pharmaceuticals Oy shares are held by institutional investors. 18.2% of Ergomed shares are held by insiders. Comparatively, 31.8% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryErgomed beats Faron Pharmaceuticals Oy on 9 of the 10 factors compared between the two stocks. Get Faron Pharmaceuticals Oy News Delivered to You Automatically Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FARN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FARN vs. The Competition Export to ExcelMetricFaron Pharmaceuticals OyBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£277.90M£136.77M£5.70B£3.02BDividend YieldN/A3.74%4.58%5.02%P/E Ratio-5.543.7828.39160.65Price / SalesN/A4,471.55427.44278,114.26Price / Cash20.0013.1936.2227.97Price / Book0.1142.328.674.70Net Income-£60.23M-£90.99M£3.25B£5.90B7 Day Performance1.25%4.86%4.30%0.40%1 Month Performance8.95%8.36%10.57%7.09%1 Year Performance35.74%195.82%35.68%73.21% Faron Pharmaceuticals Oy Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FARNFaron Pharmaceuticals OyN/AGBX 207+2.2%N/A+45.8%£277.90MN/A-5.5434ERGOErgomedN/AN/AN/AN/A£701.00M£152.09M4,641.386SLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech Health1.922 of 5 starsGBX 137+2.7%GBX 455+232.1%-17.7%£411.52M£521.32K-5.62300News CoverageHigh Trading VolumeOXBOxford BiomedicaN/AGBX 357-1.5%GBX 390+9.2%+9.9%£379.50M£98.31M-2.65891Gap DownHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919BVXPBioventixN/AGBX 2,738+0.5%N/A-37.3%£143.37M£13.65M17.7112News CoverageGap DownCIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down4BB4basebioN/AGBX 1,000flatGBX 1,600+60.0%-35.1%£128.10M£311K-1,282.05101Gap UpHigh Trading Volume Related Companies and Tools Related Companies Ergomed Alternatives Silence Therapeutics Alternatives PureTech Health Alternatives Oxford Biomedica Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Verona Pharma plc (VRP.L) Alternatives Arix Bioscience Alternatives Bioventix Alternatives Circassia Group Alternatives 4basebio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:FARN) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Share Faron Pharmaceuticals Oy With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
